Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Big -35% hit today: Aug 1 (Reuters) - Keryx Biopharmaceuticals Inc said it was withdrawing its full-year forecast due to issues related to the production of its only approved drug, Auryxia. The company said on Monday there had been an interruption in the supply of the renal drug and that it expected to make it available to patients from the fourth quarter. Keryx had earlier forecast net sales of $31 million-$34 million for Auryxia in the United States this year. Auryxia had U.S. net sales of $8.3 million in the second quarter compared with $1.8 million in year-earlier quarter.
Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia® (ferric citrate) http://finance.yahoo.com/news/keryx-biopharmaceuticals-announces-u-fda-154213869.html
